Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: A short novel for SGE1

But as long as „THEY are not ready“, someone will tell us, that the open Re-Exams and the lack of M&A and the control by TPL and Mr. Pohl’s daughter of his grand nephew etc. are responsible for the uncertainty and thus the low shareprice.

I don't disagree one iota that Swartz is responsible for our current position, I'm sure neither would SGE, considering the content of a good many posts by us... but that wasn't the issue of the discussion..

As per SGE..

I suspect a piece of minutia to which you refer has to do with the USPTO activities, and perhaps the M&A activities.  It seems many here think THOSE are the big issues, and that positives on those fronts are more likely to be catalysts for a big PPS move than the financials.  I obviously disagree.  It's the money!

I disagree whole heartedly in the classifiing of the USPTO Reexams of the '336, '148, '749 & '584 as minutia, and stated as much. 

Now taking Deb's latest post into account..  Our strong Markman in Judge Wards Court I'm sure holds a lot of weight.. and only one Claim in question in the '584 Appeal needing to be reversed is absolutely do-able.. but until I see Notice of Intent to Issue a Reexam Certificate in the PTO's case filings I will continue to have some level of uncertainty.. I'm envious of those who don't..

Obviously I look forward to seeing this finally trade without any influence from Swartz

jmo.. regards

 

 

 

Share
New Message
Please login to post a reply